FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297999281> ?p ?o ?g. }

• W4297999281 abstract "We sought to evaluate the efficacy and safety of conventional transcatheter arterial chemoembolization (cTACE) sequentially combined with systemic treatment by programmed cell death protein 1 (PD-1) inhibitor and anti-angiogenesis tyrosine kinase inhibitor (Anti-angiogenesis TKI) in patients with unresectable hepatocellular carcinoma (HCC).One hundred and forty-seven advanced HCC patients who received PD-1 inhibitors and TKIs as first-line systemic treatment between August 2019 and April 2021 were collected retrospectively. Fifty-four patients were finally included and divided into cTACE and no-cTACE groups, according to whether cTACE treatment was performed within 8 weeks before systemic treatment. The tumor objective response ratio (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between the groups. Significant factors affecting PFS and OS were determined by Cox regression.Thirty-one patients received cTACE followed by systemic treatment and 23 patients received systemic treatment only. The ORRs of the cTACE group were 48.4% (after two cycles of systemic treatment) and 51.6% (after four cycles of systemic treatment), while those of the no-cTACE group were only 17.4% and 21.7%. cTACE patients also had a longer median PFS (11.70 vs. 4.00 months, P = 0.031) and median OS (19.80 vs. 11.6 months, P = 0.006) than no-cTACE patients. Regression analyses indicated that cTACE therapy and Eastern Cooperative Oncology Group performance status were independent risk factors for PFS and OS. AEs by type were similar between the cTACE and no-cTACE groups, except for liver function injury, which was more common among cTACE patients. Fourteen patients suffered with grade 1-2 of rash in 21 patients with objective response, while only 10 patients suffered with rash in 33 patients without objective response, the adjusted hazard ratio (HR) was 4.382 (1.297-14.803).The combination of cTACE and PD-1 inhibitors and anti-angiogenesis TKIs as therapy significantly improved markers of treatment efficacy, including ORR, PFS, and OS, in unresectable HCC patients, while no more serious AEs recorded in this population compared to those receiving systemic treatment alone. Skin rash might be a predict factor to the efficacy of PD-1 inhibitors and TKI treatment." @default.
• W4297999281 created "2022-10-01" @default.
• W4297999281 creator A5004962431 @default.
• W4297999281 creator A5013735999 @default.
• W4297999281 creator A5016965374 @default.
• W4297999281 creator A5017530435 @default.
• W4297999281 creator A5023755501 @default.
• W4297999281 creator A5037415607 @default.
• W4297999281 creator A5046787436 @default.
• W4297999281 creator A5064657543 @default.
• W4297999281 creator A5085661325 @default.
• W4297999281 date "2022-09-29" @default.
• W4297999281 modified "2023-10-16" @default.
• W4297999281 title "The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study" @default.
• W4297999281 cites W1971837077 @default.
• W4297999281 cites W2010265466 @default.
• W4297999281 cites W2062030781 @default.
• W4297999281 cites W2092759077 @default.
• W4297999281 cites W2135336122 @default.
• W4297999281 cites W2142426633 @default.
• W4297999281 cites W2236150109 @default.
• W4297999281 cites W2268557403 @default.
• W4297999281 cites W2286222994 @default.
• W4297999281 cites W2289095651 @default.
• W4297999281 cites W2606367731 @default.
• W4297999281 cites W2741755269 @default.
• W4297999281 cites W2765956675 @default.
• W4297999281 cites W2996066981 @default.
• W4297999281 cites W3000125713 @default.
• W4297999281 cites W3025022288 @default.
• W4297999281 cites W3093964219 @default.
• W4297999281 cites W3094602125 @default.
• W4297999281 cites W3121807241 @default.
• W4297999281 cites W3136507564 @default.
• W4297999281 cites W3152761256 @default.
• W4297999281 cites W3165018140 @default.
• W4297999281 cites W3165752903 @default.
• W4297999281 cites W3166753505 @default.
• W4297999281 cites W3190247634 @default.
• W4297999281 cites W3198598251 @default.
• W4297999281 cites W3204422329 @default.
• W4297999281 cites W4200032204 @default.
• W4297999281 cites W4200466275 @default.
• W4297999281 cites W4210681122 @default.
• W4297999281 cites W4210756949 @default.
• W4297999281 cites W4214681573 @default.
• W4297999281 cites W4220885924 @default.
• W4297999281 doi "https://doi.org/10.3389/fonc.2022.941068" @default.
• W4297999281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36248989" @default.
• W4297999281 hasPublicationYear "2022" @default.
• W4297999281 type Work @default.
• W4297999281 citedByCount "0" @default.
• W4297999281 crossrefType "journal-article" @default.
• W4297999281 hasAuthorship W4297999281A5004962431 @default.
• W4297999281 hasAuthorship W4297999281A5013735999 @default.
• W4297999281 hasAuthorship W4297999281A5016965374 @default.
• W4297999281 hasAuthorship W4297999281A5017530435 @default.
• W4297999281 hasAuthorship W4297999281A5023755501 @default.
• W4297999281 hasAuthorship W4297999281A5037415607 @default.
• W4297999281 hasAuthorship W4297999281A5046787436 @default.
• W4297999281 hasAuthorship W4297999281A5064657543 @default.
• W4297999281 hasAuthorship W4297999281A5085661325 @default.
• W4297999281 hasBestOaLocation W42979992811 @default.
• W4297999281 hasConcept C121608353 @default.
• W4297999281 hasConcept C126322002 @default.
• W4297999281 hasConcept C143998085 @default.
• W4297999281 hasConcept C197934379 @default.
• W4297999281 hasConcept C2776056115 @default.
• W4297999281 hasConcept C2778019345 @default.
• W4297999281 hasConcept C2778455285 @default.
• W4297999281 hasConcept C2778820342 @default.
• W4297999281 hasConcept C2780394083 @default.
• W4297999281 hasConcept C71924100 @default.
• W4297999281 hasConcept C90924648 @default.
• W4297999281 hasConceptScore W4297999281C121608353 @default.
• W4297999281 hasConceptScore W4297999281C126322002 @default.
• W4297999281 hasConceptScore W4297999281C143998085 @default.
• W4297999281 hasConceptScore W4297999281C197934379 @default.
• W4297999281 hasConceptScore W4297999281C2776056115 @default.
• W4297999281 hasConceptScore W4297999281C2778019345 @default.
• W4297999281 hasConceptScore W4297999281C2778455285 @default.
• W4297999281 hasConceptScore W4297999281C2778820342 @default.
• W4297999281 hasConceptScore W4297999281C2780394083 @default.
• W4297999281 hasConceptScore W4297999281C71924100 @default.
• W4297999281 hasConceptScore W4297999281C90924648 @default.
• W4297999281 hasFunder F4320321001 @default.
• W4297999281 hasFunder F4320322665 @default.
• W4297999281 hasFunder F4320335767 @default.
• W4297999281 hasFunder F4320336572 @default.
• W4297999281 hasLocation W42979992811 @default.
• W4297999281 hasLocation W42979992812 @default.
• W4297999281 hasLocation W42979992813 @default.
• W4297999281 hasOpenAccess W4297999281 @default.
• W4297999281 hasPrimaryLocation W42979992811 @default.
• W4297999281 hasRelatedWork W2073855200 @default.
• W4297999281 hasRelatedWork W2083650117 @default.
• W4297999281 hasRelatedWork W2117726703 @default.
• W4297999281 hasRelatedWork W2141896878 @default.
• W4297999281 hasRelatedWork W2356918548 @default.
• W4297999281 hasRelatedWork W2360450127 @default.

• next